EMA is Updating the Prescribing Information for Lapatinib
Re-analysis of data on use of breast cancer medicine lapatinib following treatment with trastuzumab
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1538 results
EMA Recommends Refusal of a Marketing Authorisation for Cabazitaxel Teva
Developed as a hybrid medicine, it was expected to be used for treatment of prostate cancer
FDA Approves Ivosidenib as First-Line Treatment for AML with IDH1 Mutation
It is approved in patients who are at least 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy
Patients aged 75-79 years at higher risk of distant recurrence than patients aged 70-74 years in the older population (>70 years) of patients with early stage breast cancer despite higher competing mortality
Risk of recurrence and competing mortality in older patients
EMA Recommends an Extension of Therapeutic Indication for Olaparib
New indication concerns maintenance treatment of adult patients with advanced BRCA1/2-mutated high-grade epithelial ovarian cancer
De-escalation of Commonly Used Bone-Treating Agents Is A Reasonable Treatment Option for Patients with Bone Metastases from Breast Cancer
The frequency of administration of bone-treating agents did not affect Quality of Life outcomes
Molecular Analysis of Samples from the AURORA Programme Is Underway
Integrated molecular analyses shed light on alterations correlated with disease progression and therapeutic resistance in metastatic breast cancer
EMA Recommends Granting a Conditional Marketing Authorisation for Cemiplimab
It is indicated for the treatment of advanced cutaneous squamous cell carcinoma
The results of the ANNOUNCE study show that olaratumab with doxorubicin does not prolong the lives of patients with soft tissue sarcoma
The results of the ANNOUNCE study show that olaratumab with doxorubicin does not prolong the lives of patients with soft tissue sarcoma
EMA Recommends Granting a Marketing Authorisation for Talazoparib
It received a positive opinion for the treatment of adult patients with germline BRCA1/2 mutations who have HER2-negative locally advanced or metastatic breast cancer
Ovarian Cancer Organoids
A biobank of ovarian cancer organoids provide resource for research and precision medicine
A Spotlight on Precision Cancer Medicine
Results fromtheTARGET, I-PREDICT and WINTHER studies released